A Randomized Phase 2 Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)

Bookmark
Investigational drug late phase More information Active drug More information Moderate burden on patient More information

Trial Details

Sponsor: Brian Rini (other)

Phase: 2

Start date: Sept. 23, 2025

Planned enrollment: 120

Trial ID: NCT07188896
Copy trial ID
More trial details at ClinicalTrials.gov More info

chevron Show Summary from Sponsor

Investigational Drug AI Analysis

chevron Show for: fianlimab (REGN3767)

TrialFetch AI Analysis

Goal: To compare antitumor activity and safety of dual checkpoint blockade with fianlimab plus cemiplimab, with or without ipilimumab, versus standard ipilimumab plus nivolumab as first-line therapy for advanced clear cell renal cell carcinoma.

Patients: Adults (≥18 years) with advanced (not amenable to curative surgery or radiotherapy) or metastatic AJCC stage IV renal cell carcinoma with a clear cell component, measurable disease by RECIST 1.1, Karnofsky performance status ≥70%, adequate organ function, and no prior systemic therapy for RCC (including no prior neo/adjuvant systemic therapy). All IMDC risk groups are eligible. Key exclusions include need for chronic immunosuppression (≥10 mg prednisone equivalent/day), recent/active autoimmune disease requiring systemic therapy, history of myocarditis, CNS metastases as defined by protocol, active infection requiring systemic therapy, pregnancy/breastfeeding, and recent live attenuated vaccination.

Design: Randomized, open-label, three-arm phase 2 trial with planned enrollment of 120 patients. Randomization is 2:2:1 to Arm A (triplet), Arm B (doublet), or Arm C (active comparator), with follow-up for efficacy and safety endpoints extending up to 5 years.

Treatments: Arm A investigates IV fianlimab plus IV cemiplimab combined with IV ipilimumab. Arm B investigates IV fianlimab plus IV cemiplimab. Arm C is the standard active comparator of IV ipilimumab plus IV nivolumab, with nivolumab continued after the combination phase per usual approach. Fianlimab is a fully human IgG4 anti–LAG-3 monoclonal antibody designed to relieve LAG-3–mediated T-cell inhibition and augment antitumor immunity; it is being paired with PD-1 blockade (cemiplimab) to enhance T-cell activation through complementary checkpoint pathways. The most mature clinical experience has been in advanced melanoma, where fianlimab plus cemiplimab produced objective responses in roughly 6 of 10 anti–PD-1–naïve patients and a median PFS on the order of a year; activity was substantially lower in patients previously treated with anti–PD-1 for advanced disease. Reported safety has generally resembled PD-1–based therapy, with notable immune-related events including a higher-than-typical incidence of adrenal insufficiency, underscoring the need for endocrine monitoring.

Outcomes: The primary endpoint is objective response rate (confirmed CR+PR by RECIST 1.1) assessed over 2 years. Secondary endpoints include median PFS, 12- and 24-month PFS rates, duration of response, treatment-free survival (including characterization of time on/off therapy and time with grade ≥3 treatment-related toxicity), and treatment-related adverse event and serious adverse event rates graded by CTCAE v5 over up to 5 years.

Burden on patient: Moderate. Treatment is entirely intravenous across all arms, requiring frequent infusion visits similar to standard immune checkpoint regimens in metastatic RCC. Imaging and response assessments by RECIST 1.1 over a prolonged follow-up period add ongoing visit and scan requirements, but these are broadly consistent with routine practice for first-line metastatic RCC trials. A mandatory provision of archival tumor tissue (preferably recent and from a metastatic site) is required; this may necessitate an additional biopsy if adequate tissue is not available, increasing burden for some patients. No intensive phase 1–style pharmacokinetic sampling is described, and safety monitoring is typical for multi-agent immunotherapy (laboratory monitoring and vigilance for immune-related toxicities, including endocrine events).

Last updated: Feb 2026

Eligibility More information

chevron Show Criteria

Sites (1)

Sort by distance to:
Clear

Vanderbilt-Ingram Cancer Center

Nashville, Tennessee, 37232, United States

[email protected] / 615-343-6584

Status: Recruiting

Back to trials list